are the a subunits which serve as calcium conductance adrenergic receptors [29, [44] [45] [46] . Specifically, beta-adren-1 pores whilst the auxiliary subunits (b, a / d) modulate ergic receptor activation regulates calcium-channels by 2 function [22, 26] . cAMP-dependent protein kinase-A phosphorylation of the Calcium-channel blockers are responsible for concen-L-type calcium-channel a -subunit thereby reducing cal-1 tration-and dose-dependent inhibition of L-type calciumcium influx [29] . Accordingly, beta-blockers modulate channels [16, 32] . The action is highly tissue-specific and calcium fluxes indirectly but have little apparent direct more-or-less confined to the heart and vascular wall. The effect on calcium-channels [3] . development of the most commonly used agents arose from empiric observation rather than systematic drug design [7, 33] . The convenient short-hand grouping tends to 3. Calcium-channel blockers: model experimental conceal their chemical diversity but this is revealed in their systems individual pharmacology and patterns of therapeutic efficacy [32] .
The ouabain-model of arrhythmia in the paper of Singh Verapamil, the prototype calcium-channel blocker, was and Vaughan-Williams [9] is principally the result of developed from its parent, papaverine, as a coronary delayed afterdepolarizations and triggered activity [47] . vasodilator [7, 33] . It remains, after almost four decades,
The antiarrhythmic action of calcium-channel blockers the calcium-channel blocker of usual choice in the manhave also been studied using ischemia and reperfusion [48] agement of cardiac arrhythmias. L-type calcium-channel or electrically induced ventricular fibrillation [49] . The blockers are categorised into three distinct groups based on clinical relevance of the ouabain and ischemia-reperfusion structure: phenylalkylamines (e.g. verapamil, gallopamil), models to most clinically relevant arrhythmias is questhe benzothiazepines (e.g. diltiazem), and the dihydrotionable and underlines the few available relevant tractable pyridines (e.g. nifedipine, amlodipine, isradipine, nicaranimal models [50] . Interestingly there is a model-indipine) [32] . Phenylalkylamines and benzothiazepines dependent cross-species similarity in that macro-re-entrant stereo-selectively interact with high-affinity binding doventricular arrhythmias are almost invariably insensitive to mains on the a -subunit of the channel complex and L-type calcium-channel blockers [51] correlating well with 1 produce a block with electrophysiologically useful actions clinical experience [2] . Indeed verapamil, diltiazem and [32, 34] . Dihydropyridines are essentially devoid of electromibefradil tend to increase both the rate and duration of physiological action in vivo but at the bench have been the ventricular tachycardia in animal models [52] . more important reagents in the analysis of ion channel Clinical observations have contributed disproportionatefunction [22, 35] .
ly to an understanding of the integrated action of calciumCalcium-channel block may also result with agents channel blockers which in turn has also highlighted having other dominant electrophysiological effects [3] . For potential arrhythmia mechanisms [53, 54] . The most strikexample, azimilide, aimed principally at potassium chaning examples of the imputation of mechanism are with nels blocks L-type calcium-channels at clinically relevant atrio-ventricular re-entrant arrhythmias and normal heart concentrations [36] whilst dofetilide and E4031 have little ventricular tachycardia [53] . These examples were used as effect [3] . The overall electrophysiological importance of prominent illustrations of the vulnerable parameter conthese observations is unknown but may well be implied cept in the Sicilian Gambit [53, 55] . Indeed triggered from the observations of future clinical trials. Support for activity was suggested as a mechanism in idiopathic left the notion that calcium-channel blockade may be a useful ventricular tachycardia (ILVT) based on verapamil senadjunctive drug action comes from studies of amiodarone sitivity [54, 56] . Of course, caution is required in interpreta- [24, 25, 37, 38] . Amiodarone binds to and then blocks tions based simply on drug sensitivity and re-entry rather calcium-channels predominantly during the inactive or than triggered activity is now the perceived mechanism of resting state [39] associated with the suppression of ILVT [54, 56] . calcium-dependant action potentials in vitro [37, 40] . The clinical correlate is the well documented amiodarone-in-3.1. Voltage-gated calcium-channels and cardiac duced slowing of atrio-ventricular conduction the characarrhythmias teristics of which are most consistent with underlying calcium current inhibition [37, 40] . Other drugs that inhibit Calcium-channel blockers exert little or no effect on calcium-channels include propafenone, [41, 42] , flecainide atrial, ventricular, His-Purkinje or bypass tract conduction [3], and terfenadine [43] . Terfenadine is interesting in that or refractoriness [2,5,16] and have no action on macro-reit inhibits the L-type calcium-channels with an IC of entrant ventricular arrhythmias in either animal models 50 21 0.14 mmol l , similar to that for the inhibition of I and
[51] or in patients [2] . The principal aims of the drug Kr also within the range of clinically relevant concentrations treatment of arrhythmias are the reduction of both symp-
21
(0.01-0.1 mmol l ) [43] . toms and risk. Calcium-channel blockers may occasionally There is a large literature and considerable debate reduce risk in the occasional rare case of polymorphic regarding the interaction of calcium-channels and betaventricular tachycardia due to coronary artery spasm [57] but otherwise calcium-channel blockers are more common-3.3. Calcium-channel blockers: afterdepolarizations and ly associated with enhanced risk in a range of patient triggered activity groups (Ref. [58] and see below).
Occasional arrhythmias occurring in the structurally normal heart are due to triggered activity [47] . The clinical 3.2. Calcium-channel blockers: modulation of relevance of triggered activity is not totally clear but early conduction across the atrio-ventricular junction and late afterdepolarizations are associated [47, 62] . Early afterdepolarizations are triggered by an increased influx of The most striking clinically useful action of calciumcalcium during prolonged repolarization leading to calcium channel blockers are on the atrio-ventricular node overload and occur especially with potassium channel [4, 13, 24] . The first successes were predicted by the dysfunction as in congenital and acquired long-QT knowledge that the slow calcium current is critical to syndromes [47] . Diltiazem suppresses cesium-induced atrio-ventricular node function [59] . In the first invasive early afterdepolarizations in vivo supporting a role for electrophysiological studies prolongation of atrio-ventricucalcium-channels [47, 63] . There are few reports of callar junctional conduction by verapamil was beautifully cium-channel blockers being used to suppress early afterdemonstrated and associated with lengthening of both depolarizations: torsade de pointes has been suppressed by anterograde and retrograde atrio-ventricular node refracverapamil in atrio-ventricular block [64] and the shorttoriness [60] . The macro-electrophysiological responses of coupled variant of torsade de pointes is also responsive to the atrio-ventricular node have now been examined in verapamil [65] . It is also just possible that the incidence of detail [2, 5] . One key observation is that calcium-channel amiodarone-induced torsade de pointes is less than prerecovery from inactivation is time-dependent even after dicted due to its action as a calcium-channel blocker repolarization is complete [24] . This accounts for de- [25, 66] . cremental responses to premature stimulation and is exaggRight ventricular outflow tract tachycardia is thought to erated with both verapamil and diltiazem [2] . Interestingly, be the result of triggered activity against a background of also, effects of both verapamil and diltiazem on atriocytosolic calcium overload and oscillatory calcium release ventricular nodal refractoriness are dependent on underlyfrom the sarcoplasmic reticulum [67] . This mechanism is ing rate (Fig. 1) [59, 61] . This links in to the in vitro data supported by its induction by burst pacing and intravenous demonstrating state-dependency of heterologously exisoproterenol and relative lack of response to programmed pressed calcium-channels [22] .
stimulation. However, idiopathic left ventricular tachycarIn general diltiazem and verapamil have similar antiardias (both intrafascicular verapamil-sensitive and adenorhythmic efficacy when directed at the atrio-ventricular sine-sensitive) were also initially thought to be due to node although more data are available on verapamil [4, 24] . triggered activity (see above) [54, 56] . The ouabain-induced It should be borne in mind, especially with dihydroarrhythmias in Vaughan-Williams and Singh's paper [9] are pyridines, that reflex sympathetic activation may counmost likely the result of delayed afterdepolarizations [47] . teract any direct electrophysiological effects producing sudden increases in heart rate [2].
Calcium-channel blockers: heart failure and hypertrophy
Widespread molecular and cellular changes affecting calcium handling characterise the hypertrophic and failing heart [68] [69] [70] . These changes are complex and controversial [68] . The prediction of the nature of drug-receptor interactions under these conditions is further complicated by the fact that with the onset of heart failure drug-binding sites may have modified characteristics [68] .
Altered calcium homeostasis is thought relevant to the generation of ventricular arrhythmias in heart failure although how is not clear [71] . What is known is that in animal models arrhythmias are not suppressed by calciumchannel blockers and indeed may get worse (see above) [68] . Clinical observation suggest serious questions regarddiltiazem-induced increases (mean6SEM) in AH interval at slow and fast ing the safety of most calcium-channel blockers in patients cycle lengths (CL). Diltiazem caused dose-dependent increases in AH with heart failure [71, 72] . The exception seems to be with interval. Greater changes in AH interval were observed during pacing at amlodipine that has been reported to reduce mortality in faster cycle lengths. *P,0.05 AH interval at fast CL versus AH interval at slow CL. Reproduced with permission from Ref. [61] .
patients with non-ischemic heart failure [73] . Whether these changes, bad or good, represent arrhythmia-related 4.1. Calcium-channel blockers: drug-receptor phenomena remains unknown [71, 72] . interactions
The binding characteristics and, accordingly, the actions of the different groups of L-type calcium-channel blockers 4. Molecular pharmacology of calcium-channel are qualitatively and quantitatively distinct [22, 35, 77] . blockers These characteristics arise from state-dependent interactions with individual subclasses of channel receptor leadCalcium currents were first recorded in cardiac ing on to the observed pharmacological discrimination and myocytes which continue to provide a robust and highly relative selectivity of action [22] . Calcium-channel blockuseful experimental system allowing many key properties ers interact at a set of allosterically linked sites on the to be examined [22, 74, 75] . The characterization of cala-subunit of the L-type calcium-channel localised in the cium-channel function here has been significantly assisted pore-forming region of the L-type calcium-channel a -1 using calcium-channel blockers [22] . Of interest is that subunit [35] . These sites have been identified by a combiwhilst phenylalkylamines and benzothiazepines are the nation of techniques that have included site-directed more effective antiarrhythmic agents dihydropyridines mutagenesis, photoaffinity labelling and chimeric a -1 have been the more important for mechanistic studies (see subunit construction [22, 35] . above) [3] .
Verapamil and diltiazem block channels mostly from the For the purposes of the analysis of the molecular basis inside surface of the membrane by entering the channel of the drug-ion channel interaction the calcium-channel is preferentially when open [22, 35, 77] . In simple terms there best considered as a pharmacological receptor with specific is use-dependent block with benzothiazepines and sites for the binding of activator and antagonist ligands phenylalkylamines but not with dihydropyridines [22] . [35] . The availability of cloned channels usually examined This open-channel block with slow recovery of the channel heterologously in combination with new molecular and results in pronounced frequency-dependency which contrielectrophysiological assays has provided a great deal of butes to the efficacy of verapamil and diltiazem with information on the determinants of antiarrhythmic drug tachycardia [24] . State-dependent interactions contribute to binding and action (Fig. 2) [22, 76] .
our understanding of the antiarrhythmic action of the phenylalkylamines and benzothiazepines in the atrio-vensium channels [82, 83] . In recent studies transfection of tricular node [24, 61] . Diltiazem use-dependent block is HERG or KvLQT1 /IsK coding sequences into various cell qualitatively indistinguishable from that due to lines has demonstrated that verapamil is a potent antagophenylyalkylamines [34, 78] .
nist of HERG-encoded channels occurring at clinically The selective modulation of T-type calcium-channels relevant concentrations (Fig. 3) [82, 83] . The actual contriprovided an attractive idea for drug design due to T-type bution of this inhibition to clinical effects remains however channel localization in pacemaker regions [31] . The use of unknown. channel-specific drugs was thought likely to avoid some of the troublesome peripheral side-effects seen with L-type receptor blockers [31] . The benzimidazolyl-substituted 5. Calcium-channel blockers and arrhythmias: teraline derivative, mibefradil, selectively inhibits T-type current perspectives calcium-channels in vitro at concentrations that partially block L-type calcium-channels [31] . The drug shortened Calcium-channel blockers do not reduce mortality but action potential duration without any reported important often decrease symptoms and improve the quality-of mechanism under these circumstances could invoke neurohumoral activation with abrupt changes in blood pressure leading to b-adrenergic enhanced influx of calcium through L-type calcium-channels [86] . How important such a mechanism will turn out to be is unclear.
Many observations show that calcium-channel blockers do not reduce mortality when given during or after myocardial infarction and they are not recommended as standard treatment [58, 87] . The position of calcium-channel blockers in hypertension is currently unclear [19] . Taken together these data have led to several recommendations. Patients with coronary artery disease, for example, should not receive short-acting dihydropyridines although verapamil may be an alternative to b-blockers in those with unstable angina [17,88].
Calcium-channel blockers and arrhythmias: future prospects
There are several reasons for thinking that calciumchannel blocker use will increase in patients with arrhythmias. First, although the indications often differ they are probably relatively safe when compared with other direct ion channel modulating drugs [11, 32, 84] . Second, the large body of work on molecular binding and structural diversity is likely to generate ideas providing new drugs that may enhance the hitherto powerful combination of low toxicity, reasonable tolerability and relatively high efficacy of verapamil and diltiazem [23] . Such approaches may be classic work showing electrical re-modelling in the goat atrial fibrillation model [94] . Intracellular calcium was felt despite a general decline in antiarrhythmic drug use [84] to be a potential determinant of re-modelling and this the use of calcium-channel blockers increased after the contention is now supported by the observation of delayed publication of CAST [85] . In the National Ambulatory recovery from electrical re-modelling with the administraMedical Care Survey the percentage of patients with atrial tion of calcium gluconate [92] and reduced re-modelling fibrillation taking calcium-channel blockers was 12.1% in with verapamil [90] [91] [92] [93] . Further, it is now suggested from 1989-1991 and 21.1% in 1992-1993 [85] .
retrospective analysis that compounds that are likely to More recently the fortunes of some drug formulations in result in a lowered cytosolic calcium such as verapamil this class have not been so good. The recent much and beta-blockers reduce the risk of relapse following discussed meta-analysis of patients with coronary artery cardioversion (Fig. 4) [95] . Fourth and possibly more disease but without clinical arrhythmias demonstrated a speculative is the potential exploitation of altered relationdose-dependent increased risk of total mortality when ships between calcium influx via L-type calcium-channels short-acting nifedipine was compared to diuretics or betaand calcium release from the sarcoplasmic reticulum in blockers [18] . Albeit indirect a potential proarrhythmic heart failure [96] [97] [98] . Altered sparks and quarks may point is being addressed prospectively and these data will also be relevant [19, 101, 102] . There remains of course much basic and clinical research to clarify mechanisms and ensure optimum use. Finally, it seems possible that calcium-channel blockade as has been raised by amiodarone [24, 25] . In a meta- suggest that whether in a class of their own or not, 
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